NEW YORK (GenomeWeb News) — Invitrogen will exclusively market pharmaceutical-grade insulin made by Indian biotech Biocon to global cell-culture customers, Invitrogen said yesterday.
Invitrogen said Biocon’s insulin is equivalent to others used for cell-culture bio-manufacturing and in delaying apoptosis in mammalian cell cultures.
This agreement will enable the companies to offer scientists “a competitive alternative” to other human insulin suppliers, who offer a pharmaceutical-grade product only in bulk, said Jeff Greenberg, Invitrogen’s vice president of Bioproduction. Invitrogen will market Biocon’s insulin in volumes of 25 kg or more.
Financial terms of the agreement were not released.